A new regimen of chemotherapy was used to reduce toxicity of ABVD: adriamycin is replaced by epirubicin and dacarbazine by prednisone. Thirty eight patients with Hodgkin's disease, stage I to IIIA, previously untreated, received three courses of this regimen before radical radiotherapy. Gastro-intestinal toxicity and alopecia appeared less marked than with ABVD. Immediate efficacy is similar with 80% of complete remission (one third observed at day 28) and only 2 failures. This regimen appears thus as a clear improvement in the treatment of patients with Hodgkin's disease and deserves larger comparison with previously used chemotherapy in a more extensive controlled trial.